2023 Guidance and Q3 Earnings

67 assets in clinical development: upcoming pipeline catalysts Infectious Diseases Respiratory/Immunology Opportunity driven HIV Oncology Regulatory decision H2 2023 HT 2024 H2 2024 Jemperli³: RUBY, DMMR/MSI-H 1L EC4 Ojjaara: MOMENTUM, myelofibrosis EU EU, JP Arexvy. 50-59 YOA Nucala: CRSwNP2 Nucala: severe asthma US, EU, JP CN 220 1/152525 JP Regulatory submission and Arexvy: 50-59 YOA¹ Nucala: CRSWNP² US, EU, JP MenABCWY vaccine 1st Gen CN acceptance Jemperli³: RUBY (Part 2), 1L EC4 Jemperli³: RUBY (Part 1), 1L EC4 US, EU US, EU gepotidacin: EAGLE-2/3, uUTI10 US depemokimab: SWIFT-1/2, asthma depemokimab: ANCHOR-1/2, CRSWNP Nucala: MATINEE, COPD" Late-stage phase Ill and phase II readouts GSK gepotidacin: EAGLE-1, GC5 depemokimab: SWIFT-1/2, asthma Blenrep: DREAMM-7, 2L+ MM6 Jemperli: RUBY (Part 2), 1L EC4 Jemperli: RUBY (Part 1), 1L EC4 Zejula': FIRST, IL maintenance OC depemokimab: ANCHOR-1/2, CRSWNP² Nucala: MATINEE, COPD" cobolimab³: COSTAR, 2L NSCLC12 Blenrep: DREAMM-8, 2L+ MM6 Zejula': ZEAL, IL maintenance NSCLC 12 linerixibat: GLISTEN, PBC13 MenABCWY vaccine 2nd Gen US US US US 5 5 5 5 1. Years of age 9. Phase II 10. Uncomplicated urinary tract infection 2. Chronic rhinosinusitis with nasal polyps 3. Tesaro asset 4. Endometrial cancer 11. Chronic obstructive pulmonary disorder 5. Urogenital gonorrhoea 12. Non-small cell lung cancer 6. Multiple myeloma 7. Overall survival population 8. Ovarian cancer 13. Treatment of cholestatic pruritus in primary biliary cholangitis 12

View entire presentation